Investor Presentation - First Six Months of 2021

30 Investor presentation First six months of 2021 Novo Nordisk® Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1535 Icosema (LAIsema) - NN1965 - Insulin 965 NN1147 - Insulin 147 and PCSK9i NN9389FDC Sema - OW GIP NN1845 - GSI NN1471 - Ideal Pump Insulin NN9041 - DNA Immunotherapy NN9775 PYY 1875 analogue - NN9215 LA-GDF15 - NN9838 Cagrisema NN7533 Eclipse NN9500 FGF-21 NASH NN6434 - PCSK9i STT-5058 STATEN, Anti-ApoC3 mAb PHASE 2 NN9388 Cagrisema Cagrilintide NN9838 EX2020 Macrilen, GHD1 NN7769 Mim8 (phase 1/2) NN9931 - Gilead NASH NN6018 Ziltivekimab NN6435 Oral PCSK9i PHASE 3 NN9931 - NN6535 Semaglutide in AD NN8640 - Somapacitan - QW GHD² SUBMITTED APPROVED NN9924 Oral Semaglutide 25 and 50 mg NN1436 Insulin Icodec Semaglutide NASH SUSTAIN FORTE - Semaglutide 2.0 mg³ TresibaⓇ Semaglutide 2.4 mg4 XultophyⓇ LevemirⓇ RyzodegⓇ NovoMixⓇ FiaspⓇ NovoRapidⓇ RybelsusⓇ OzempicⓇ NN7415 Concizumab Other PHASE 3 trials - SOUL Oral semaglutide 14.0 mg CVOT FLOW-Semaglutide 1.0 mg in chronic kidney disease FOCUS - Semaglutide 1.0 mg in diabetic retinopathy - STRIDE Semaglutide 1.0 mg in peripheral arterial disease SELECT - Semaglutide 2.4 mg in obesity CVOT HFPEF Semaglutide 2.4 mg VictozaⓇ® WegovyTM 4 SaxendaⓇ NovoSevenⓇ NovoEight® EsperoctⓇ NovoThirteenⓇ Diabetes care Obesity care Rare blood disorders Rare endocrine disorders RefixiaⓇ/RebinynⓇ NorditropinⓇ SogroyaⓇ5 Other serious chronic diseases 1 Novo Nordisk only holds the commercial rights in North America; 2 Study conducted in growth hormone disorders; 3 Submitted in the EU and the US (Resubmitted on 28 May 2021); 4 Approved in the US; 5 Approved in the EU, the US and Japan, for adult growth hormone disorder; PYY: Peptide YY; QW: Once-weekly; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting insulin; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HFPEF: heart failure with preserved ejection fraction; AD: Alzheimer's Disease; FDC; Fixed-dose combination; NASH: Nonalcoholic Steatohepatitis, Cagrilintide was denoted AM833 before

View entire presentation